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 5 
ABSTRACT  6 
 7 
 8 
Objective To evaluate the effects of a therapy where patients used self-modulated functional 9 
electrical stimulation to produce or assist task-specific upper limb movements, which enabled 10 
them to engage in intensive goal-oriented training. Functional electrical stimulation was 11 
modulated by a custom device controlled through the patient’s unaffected hand. We defined 12 
our experimental intervention Electrically-Assisted Movement Therapy. Dose-matched goal-13 
oriented standard care was used as a control intervention. 14 
 15 
Design Randomized, crossover, assessor-blinded, 5-week trial with follow up at 18 weeks. 16 
This study is registered with ClinicalTrials.gov, number xxx. 17 
 18 
Setting Rehabilitation University Hospital. 19 
 20 
Participants A total of 11 chronic patients with severe stroke (mean age 47.9y), more than 6 21 
months poststroke (mean time since event 46.3mo). 22 
 2 
 23 
Interventions Each therapy consisted in 10 sessions of 90 minutes per day, five sessions per 24 
week, for two weeks. After the first 10 sessions, group allocation was crossed-over, and 25 
patients received a one-week therapy break before receiving the new treatment. 26 
 27 
Main Outcome Measures Fugl-Meyer Motor Assessment for the Upper Extremity, Wolf 28 
Motor Function Test, Spasticity, 28-Items Motor Activity Log.   29 
 30 
Results 44 individuals were recruited, of whom 11 were eligible and participated. Five 31 
patients received the experimental treatment before standard care, and six received standard 32 
care before the experimental treatment. Electrically-Assisted Movement Therapy produced 33 
higher improvements in the Fugl-Meyer scale than standard care (p<0.05). Median 34 
improvements were 6.5 and 1 Fugl-Meyer points after the experimental treatment and 35 
standard care, respectively. The improvement was also significant in subjective reports of 36 
quality of movement and amount of use of the affected limb during activities of daily living 37 
(p<0.05).  38 
 39 
Conclusions Electrically-Assisted Movement Therapy produces clinically important 40 
impairment reduction in stroke patients with chronic severe upper limb paresis. 41 
 42 
Keywords: Electrical Stimulation Therapy, Cerebrovascular Accident, Hemiplegia, Motor 43 
Skills, Rehabilitation. 44 
 3 
 45 
Abbreviations 46 
EAMT: Electrically-Assisted Movement Therapy 47 
SC: Standard Care 48 
FES: Functional Electrical Stimulation 49 
EMG: ElectromyographyFMA-UE: Fugl-Meyer Motor Assessment Upper Extremity 50 
MAL: Motor Activity LogWMFT: Wolf Motor Function Test 51 
REPAS: Resistance to passive movement 52 
MRI: Magnetic Resonance Imaging 53 
MCID: Minimal Clinically Important Difference 54 
MDC: Minimum Detectable Change 55 
CI: Confidence Interval 56 
57 
 4 
INTRODUCTION 58 
 59 
 60 
Every year, 17 million people suffer a stroke worldwide, and approximately one third of them 61 
develop permanent upper limb paresis (1). Among the available therapeutic approaches, 62 
functional electrical stimulation (FES) has been proposed as a viable intervention to increase 63 
range of motion (2) and to reduce upper limb impairment (3), ultimately improving function 64 
and participation (4). Many FES regimens and systems have been investigated (5), but clear 65 
pathophysiological explications and protocols leading to improved efficacy are still lacking 66 
(6).  67 
FES regimens for the upper limb tested in clinical studies include cyclical FES, EMG-68 
triggered FES, and neuroprosthetic FES. Cyclical stimulation produces repetitions of 69 
movements, without requiring patient’s active participation (2), and is often used in patients 70 
with severe impairments and absence of voluntary arm and hand activity. EMG-triggered FES 71 
is based on rewarding successful active attempts by the patient with a reinforcement signal in 72 
order to drive motor relearning and neuroplasticity (7). To date, these two types of stimulation 73 
have not proven superior with respect to standard care (2) or other FES families (7). 74 
Neuroprosthetic FES aims at promoting movement relearning by its ability to bypass lesions 75 
and restore function (2). Neuroprostheses proposed in the past provided meaningful upper 76 
limb movements, and could produce pre-defined muscles activation sequences upon 77 
triggering by patients or therapists (4, 8, 9). A special class of FES neuroprostheses enabled 78 
the control of FES at will by continuously detecting EMG activity, and promoted a significant 79 
reduction of impairment (8). Unfortunately, this type of self-modulated FES might be 80 
unfeasible in the severely impaired population due to abnormal or absent EMG patterns.  81 
 5 
 82 
Providing a match between the intention to move the impaired limb and continuous FES 83 
assistance during the movement can be achieved without relying on paralyzed muscles 84 
activity by providing control means to the unaffected hand of the patient.    85 
 86 
In this study, we introduce and test a therapy where patients with severe upper limb 87 
impairment self-modulate FES to produce or assist task-specific movements. A custom FES 88 
device enables them to engage in intensive goal-oriented training despite their impairment. 89 
We defined our experimental intervention “Electrically-Assisted Movement Therapy” 90 
(EAMT). During EAMT the use of the unaffected limb is limited by the need of operating the 91 
custom FES controller in order to self-modulate the delivery of electrical currents, and 92 
training is focused on the affected limb.  93 
 94 
The purpose of this study is to determine whether EAMT produces higher improvements in 95 
upper limb motor impairment, skilled function, spasticity, and subjective perception of the 96 
ability to perform daily living tasks than dose-matched goal-oriented standard care (SC) in 97 
patients with severe upper limb paresis, more than six months after their stroke. This pilot 98 
study was designed in order to establish the presence of a clinically important effect on the 99 
selected population, and to estimate treatment effect sizes for further clinical testing (10). 100 
 101 
METHODS 102 
 103 
 104 
 6 
  Trial design 105 
This study involved random allocation of patients and cross-over group assignment. This 106 
protocol was reviewed and approved by the xxx. This study is registered with 107 
ClinicalTrials.gov, number xxx.  108 
 109 
  Participants 110 
Subjects of both genders, aged between 18 and 75, were eligible if they met the following 111 
inclusion criteria: diagnosis of one, first ever ischemic stroke verified by brain imaging (CT or 112 
MRI); chronic impairment after stroke (>6 months); no contraindications to neuromuscular 113 
electrical stimulation. Subjects were excluded if they showed unstable recovery stage, i.e. 114 
difference between two baseline examinations >1 point in the motor part of the Fugl-Meyer 115 
Assessment for the Upper Extremity scale (FMA-UE) (11), mild-to-moderate impairment of 116 
the upper extremity (FMA-UE≥21), or excessive spasticity (median Ashworth Scale of the 117 
upper limb >2).  118 
  Interventions 119 
Electrically-assisted movement therapy (EAMT) was achieved by using a custom FES device 120 
allowing patients to control and modulate the electrical stimulation using the unaffected hand 121 
in order to produce task-specific movements of the affected limb. The system allowed 122 
therapists to choose and reproduce movements of the whole paralyzed upper limb, re-123 
engaging patients into goal-oriented exercises.  124 
 125 
Whenever the patient had difficulties in simultaneously controlling the device and performing 126 
exercises, the therapist provided help and ensured the use of the affected limb. During each 127 
 7 
session three types of exercises were possibly performed: mobilization, games, and training 128 
for activities of daily living (ADL). Therapy was provided in 10 sessions of 90 minutes per 129 
day over two consecutive weeks. 130 
 131 
SC consisted in goal-oriented occupational therapy delivered as mobilization, games, and 132 
training for ADL. Therapy was provided in 10 sessions of 90 minutes per day over two 133 
consecutive weeks, to match the amount of EAMT. Standard care (SC) always excluded FES, 134 
CIMT, and Robotic training. 135 
 136 
Progressive exercise shaping, behavioral training towards transfer of exercises to ADL, and 137 
daily administration of the Motor Activity Log (MAL) (12) were applied to both 138 
interventions, as formerly proposed in other effective treatments (13, 14).  139 
 140 
There were two investigation groups: EAMT-SC, where EAMT preceded SC, and SC-EAMT, 141 
where SC preceded EAMT. 142 
 143 
  Outcomes 144 
The primary outcome measure was the change in FMA-UE. The threshold for assessing a 145 
minimal clinically important difference (MCID) between groups was set to 5.25 points (15), 146 
and the minimum detectable change (MDC) between groups was 5.2 points (with no 147 
differentiation by severity of impairment) (16, 17). 148 
 149 
 8 
Secondary outcome measures were: Wolf Motor Function Test (WMFT) (18); Resistance to 150 
Passive Movement (REPAS) to test hand and arm spasticity (19); MAL (12). Stroke type was 151 
classified using the Bamford classification (21). 152 
 153 
For each patient,  brain lesions were delimited and measured (size) using the Medical Imaging 154 
Interaction Toolkit software from structural MRI acquired before trial start. Therapy was 155 
delivered at the xxxx of the xxx in xxx, xxx.  156 
 157 
Clinical outcomes of patients assigned to EAMT-SC and SC-EAMT groups were collected at 158 
T0 (baseline), at T1 (week 3), T2 (week 6), and T3 (follow-up, week 18). One week before 159 
T0, the primary outcome measure was collected for all patients to ensure they were in a stable 160 
plateau of recovery. Patients were excluded if the difference between the two baseline 161 
examinations was >1.  162 
 163 
  Sample size 164 
Sample size was determined through two-samples testing by estimating effect sizes for the 165 
two groups, assuming a statistical power of 80% and a significance level of 5%. Average 166 
treatment effects were estimated in 3.1 FMA-UE points for SC (22) and 8.35 FMA-UE points 167 
for EA. The choice of 8.35 points for EAMT is justified by the fact that, in order to be an 168 
effective treatment and yield an effect on the selected population, the therapy should be able 169 
to produce a MCID in the primary outcome. Standard deviations for both therapies were set to 170 
3 FMA-UE points (15), and accounted for the inactivity of patients that was ruled out after 171 
training. 172 
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 173 
  Randomization 174 
The allocation sequence was generated from a normally distributed pseudorandom number 175 
sequence of 12 elements in MATLAB. Patients were allocated to therapy groups upon 176 
collection of the signed consent form. Random allocation sequence was sent to one 177 
representative of xxx and one of xxx, before trial start. Representatives had no contact with 178 
the assessor nor with patients during the whole study duration. Random allocation sequence 179 
was generated at xxx, and patients were enrolled and assigned to interventions by the clinical 180 
staff at xxx. 181 
 182 
  Blinding  183 
The outcome assessor was a trained physician with more than 15 years of experience in 184 
neurological rehabilitation.  The assessor was blinded to interventions after assignment, and 185 
had no access to the room where the therapy was delivered, preventing unwanted therapy 186 
unmasking.  187 
 188 
  Statistical analyses 189 
The difference between treatment effects (EAMT vs SC) and negligible carry-over effects on 190 
primary and secondary outcomes were tested with an unpaired, two-tailed Mann-Whitney U-191 
test (23). Within-subjects differences of the relative improvements at T1 and at T2 were tested 192 
to detect a significant effect of the therapy type, and within-subjects sums of the relative 193 
improvements at T1 and T2 were tested to confirm negligible carry-over effects. Asymptotic 194 
p-values are reported in order to account for ties in the ranking procedure. 195 
 10 
Difference between treatment effects  196 
Null Hypothesis: [(R1-R2)EAMT-SC] and [(R1-R2)SC-EAMT] have equal medians, rejected if 197 
p<0.05 198 
Negligible carry-over effects 199 
Null Hypothesis: [(R1+R2)EAMT-SC] and [(R1+R2)SC-EAMT] have equal medians, rejected if 200 
p<0.05 201 
 202 
One of the patients in the SC-EAMT group dropped out from the study for unrelated medical 203 
reasons, and her evaluation at T2 was missed. For this reason, only the 10 patients that 204 
received therapy in both periods were considered to test the difference between treatment 205 
effects. All available data was used in order to estimate effect sizes (intent-to-treat).  206 
 207 
Two patients assigned to the EAMT-SC group took a longer washout period than the other 208 
patients in the group, namely eight and six weeks instead of one: evaluations were repeated 209 
before starting the second therapy period in order to check for carry-over effects (evaluation 210 
T1*). We estimated the effect of EAMT by using T0 and T1 evaluations and the effect of SC 211 
by using T1* and T2 evaluations for the two patients who received longer washout, i.e. 212 
leaving uncontrolled recovery outside analyses. Carry-over effects were checked by 213 
conservatively including uncontrolled recovery into the second therapy period, i.e. by 214 
checking for statistical differences in T1-T0 against T2-T1, for all patients.  215 
 216 
Post-hoc tests of between-groups differences of the relative improvement in primary and 217 
secondary outcome measures were tested with an unpaired, two-tailed Mann-Whitney U-test. 218 
 11 
Within-groups differences of the relative improvement in primary and secondary outcome 219 
values were tested with paired, two-tailed Wilcoxon signed-rank test. In both cases, 220 
significance levels were Bonferroni corrected to account for multiple comparisons.  221 
 222 
 223 
Differences in the occurrence of large recoveries of at least 5 FMA-UE points after either 224 
treatment were tested by means of two-tailed Chi-square test. Odds ratio of large recoveries 225 
was calculated by computing the geometrical average of the U-statistic: r=Z/√N. 226 
 227 
All calculations and statistical analyses were computed with IBM SPSS Statistics 20.  228 
 229 
RESULTS 230 
Between September 28, 2015 and January 11, 2016, 44 individuals were tested for eligibility, 231 
of whom 11 were eligible and agreed to participate. 232 
 233 
Five patients were assigned to the EAMT-SC group and six were assigned to the SC-EAMT 234 
group. Their data was included and analyzed for the primary and secondary outcome 235 
measures.  236 
 237 
Patients’ demographics and clinical characteristics at baseline are reported in Table 1,  while 238 
detailed single-patient data are shown  in Supplementary Table 1. There were no statistically 239 
significant differences between groups at baseline.  240 
 12 
 241 
Relative improvements with respect to previous evaluation in primary and secondary outcome 242 
measures are reported in Table 2, along with the corresponding p-values for the main cross-243 
over and carry-over effects.  244 
 245 
Absolute changes in primary and secondary outcome measures are reported in Table 3. 246 
 247 
----------------------- please insert Table 1, 2, and 3 approximately here ---------------------------- 248 
  Primary outcome 249 
Improvements after the first and the second period, i.e. differences between scores at T1-T0 250 
and scores at T2-T1, scored higher in the EAMT-SC group (median=16; mean rank=3.00) 251 
than in the SC-EAMT group (median=-4; mean rank=3.00), as shown in Figure 1. Mann-252 
Whitney U-value was found to be statistically significant U=3.00 (Z=-1.984), p<0.05, as 253 
reported in Table 2. The difference between recoveries was large (r=-.88), and no significant 254 
carry-over effects were found (p=0.075). 255 
 256 
----------------------- please insert Figure 1 approximately here ---------------------------- 257 
Relative improvements with respect to baseline were not significantly different between 258 
groups at T1, although the average recovery was larger in the EAMT-SC group (12.2±6.7 259 
FMA-UE points for EAMT-SC and 4.3±4.4 for SC-EAMT), nor at T2 (16.4±5.8 FMA-UE 260 
points for EAMT-SC and 8.6±4.5 for SC-EAMT). Changes in absolute FMA-UE scores are 261 
reported in Table 3 and Supplementary Figure 1. The absence of a significant difference in 262 
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recovery between groups at T2 with respect to T0 determines a negligible carry-over effect in 263 
the primary outcome measure (4). In addition, relative recovery at T2 with respect to T1 was 264 
not significantly different between groups (0.8±1.7 FMA-UE points for EAMT-SC and 265 
4.8±4.8 for SC-EAMT). Median improvements disregarding when therapies were provided 266 
were 6.5 and 1 FMA-UE points after EAMT and SC, respectively. The difference in recovery 267 
between therapies is greater than the MDC and MCID. 268 
 269 
Follow-up evaluations revealed that six of the ten patients that were assessed still reported a 270 
large recovery with respect to T0 (baseline), and three of these six patients showed a further 271 
improvement >5 FMA-UE points with respect to T2. Detailed single-patient primary outcome 272 
data are shown in Supplementary Figure 2. At the follow up evaluation, the improvement 273 
with respect to T0 was 12.4±7.8 and 12.2±10.6 FMA-UE points for the EAMT-SC and SC-274 
EAMT groups, respectively.  275 
 276 
Cumulating the effects of the two consecutive therapies, 10/11 patients achieved a large 277 
recovery. Large recoveries were more frequent after two weeks of EAMT (70% of the 278 
patients) than after two weeks of SC (27% of the patients, Chi-square=3.834, p=0.05). After 279 
EAMT, they occurred at T1 (4/5 patients) and at T2 (3/5 patients), while after SC they 280 
occurred only at T1 (3/6 patients). The odds of achieving a large recovery after receiving 281 
EAMT were 6.22 times higher than after SC (95% CI:0.9-41.3). 282 
 283 
  Secondary outcomes 284 
Significantly higher improvements after EAMT than after SC were found for self-reported 285 
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MAL amount of use (p<0.05) and MAL quality of movement (p<0.05), as shown in Figure 1. 286 
No significant carry-over effects were found in these two measures, as reported in Table 2. 287 
Recovery in FMA-UE scores was moderately correlated to recovery in MAL quality of 288 
movement scores (r=0.57, p<0.01) and MAL amount of use score (r=0.51, p<0.05). Although 289 
their change was not significant, WMFT time scores were improved at T1 and T2 with respect 290 
to T0 (EAMT-SC was 6.4±9.6 s faster at T1 and further 6.4±7.0 s faster at T2; SC-EAMT was 291 
1.3±3.3 s slower at T1 but 4.4±5.9 s faster at T2). REPAS did not change significantly during 292 
the study.   293 
 294 
Lesion volumes, reported in Supplementary Table 1, were not correlated with any relative or 295 
absolute measure of the primary outcome. 296 
 297 
DISCUSSION 298 
 299 
 300 
We have shown that self-modulated FES and intensive goal-oriented training of the affected 301 
limb result in clinically relevant reduction of impairment in chronic stroke patients with 302 
severe paresis. One and a half hours of EAMT five times a week for two weeks had 6.22 303 
times higher odds of large recovery in the primary outcome measure than dose-matched SC. 304 
Although our results in primary and secondary outcomes indicate early evidence of 305 
superiority of EAMT with respect to SC, superiority should be properly investigated in later 306 
stage clinical trials with higher statistical power. To this aim, effect sizes estimates for EAMT 307 
and SC were found to be 6.5 and 1 FMA-UE points, respectively. The difference between 308 
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these treatment effects was above the MDC and the MCID. Follow-up evaluations showed 309 
retention or further improvement of function in patients that were able to achieve substantial 310 
gains already at T2, i.e. at the end of the interventional period.   311 
 312 
This is the first time to the best of our knowledge that a therapy regimen involving self-313 
modulated FES of the affected limb results in clinically relevant improvement in patients with 314 
severe impairment. The idea of using contralateral hand to control FES is not novel (24), 315 
although former studies focused the treatment on the hand only (24, 25). As already observed 316 
in the past, the timeliness and regimens of FES produce substantially different outcomes in 317 
stroke patients (6). FES is a powerful ally of other effective treatments in neurorehabilitation 318 
for its capacity to provide limb actuation, rich afferent stimulation in sensation and 319 
proprioception, and increase cortical excitability in the short time scale (26). Our results show 320 
that combining coarse and imprecise movements generated via FES to volitional attempts and 321 
residual capability in order to complete tasks of progressive complexity can improve 322 
movement relearning and perceived functionality of the affected limb. We cannot exclude, as 323 
pointed out from recent studies (27), that some effect may arise directly from sensory 324 
stimulation coupled with goal-oriented training. Another recent study (28) has shown that 325 
EMG-triggered FES is not better than conventional care in absence of fingers extension, 326 
relating this finding to a potential involvement of corticospinal integrity (29). In our study, 327 
only one of the patients presented partial fingers extension at baseline, but nonetheless we 328 
observed large recoveries, motivating further research in self-modulated stimulation assisting 329 
training of daily living tasks.   330 
 331 
This pilot study was limited by the small sample size, and results should be replicated on a 332 
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larger population of patients. Assessor blinding and trial design ensured the absence of 333 
confirmatory bias at T1 towards one of the groups. Nevertheless, effect sizes of both groups 334 
might have been inflated by the fact that the assessor knew that patients received some form 335 
of therapy before T1 and before T2, so effect sizes should be taken cautiously.  336 
 337 
Two patients that received EAMT as first therapy took a longer washout period than 338 
scheduled, reporting consistent increases during this uncontrolled time. The statistical 339 
analyses did not include this uncontrolled recovery except for the carry-over effects. Although 340 
these effects were negligible in the context of this study, further studies should be designed to 341 
account for this potential source of bias, i.e. avoiding the cross-over design. The recovery 342 
during uncontrolled time after EAMT could be explained by the fact that both patients 343 
reported attempting to use their affected limb more often at home. 344 
 345 
In addition, the current study design did not allow us to provide an explanation regarding the 346 
difference in recovery between groups achieved in the first period of treatment with respect to 347 
the second. We speculate that this may be due to: i) allocation specific difference in 348 
motivation in patients who may see more rapid progress in one of the groups; ii) a 349 
neurophysiologic phenomenon favoring improvements within the scale of two weeks and 350 
penalizing later improvements that occur later in time; iii) small sample size, although known 351 
cofactors were balanced between groups (age, time since event, lesion type, baseline FMA-352 
UE score).  353 
 354 
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Figures  1 
Figure 1 – Clinical effects. 2 
 3 
A) Main cross-over effect in primary and secondary outcomes. The main cross-over effect is 4 
assessed by comparing the difference between the two responses to therapy between groups. In 5 
other words, each patient provides a single value indicating how much the first therapy provided 6 
a larger response than the second therapy; for the EAMT-SC group, the vector indicates how 7 
larger the improvement following EAMT was with respect to the improvement due to SC, and 8 
viceversa for the SC-EAMT group. B) Relative improvement in FMA-UE, the primary outcome 9 
measure of this study, with respect to the baseline evaluation at T0. Patients of the EAMT-SC 10 
group received EAMT between T0 and T1, and further received SC between T1 and T2. On the 11 
contrary, patients of the SC-EAMT group received SC between T0 and T1, and further received 12 
EAMT between T1 and T2.  13 
14 
2 
 
Figure 2– CONSORT flow diagram.15 
 16 
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Tables 17 
Table 1 – Baseline demographics and clinical characteristics. 18 
 19 
EAMT-SC: this group of patients received electrically-assisted movement therapy before 20 
standard care; SC- EAMT: this group of patients received standard care before electrically-21 
assisted movement therapy. TACI: Total Anterior Circulation Infarct. FMA-UE: Fugl-Meyer 22 
Assessment for the Upper Extremity.  23 
 24 
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Table 2 – Primary and secondary outcomes, relative improvement with respect to previous 25 
evaluation.  26 
 27 
Hp: statistical hypothesis that was tested; EAMT-SC≠SC-EAMT: main cross-over effect, i.e. the 28 
difference of first and second therapy effects is significantly different between groups; 29 
EAMT+SC≠SC+EAMT: carry-over effect, i.e. the sum of first and second therapy effects is 30 
significantly different between groups; statistically significant p-values are reported in bold. 31 
FMA-UE: Fugl-Meyer Assessment for the Upper Extremity; WMFT time: Wolf Motor Function 32 
Test timing (in seconds); WMFT-FAS: Wolf Motor Function Test Functional Activity Scale; 33 
REPAS: Resistance to Passive Movement Scale; MAL-AOU: Motor Activity Log Amount Of 34 
Use; MAL-QOM: Motor Activity Log Quality Of Movement. Improvements are reported as 35 
5 
 
mean ± standard deviation of the individual change within each group. EAMT-SC: this group of 36 
patients received electrically-assisted movement therapy before standard care; SC- EAMT: this 37 
group of patients received standard care before electrically-assisted movement therapy.   38 
6 
 
Table 3 – Primary and secondary outcomes, absolute group scores across the study. 39 
 40 
FMA-UE: Fugl-Meyer Assessment for the Upper Extremity; WMFT time: Wolf Motor Function 41 
Test Timing (in seconds); WMFT-FAS: Wolf Motor Function Test Functional Activity Scale; 42 
REPAS: Resistance To Passive Movement; MAL-AOU: Motor Activity Log Amount Of Use; 43 
MAL-QOM: Motor Activity Log Quality Of Movement. Scores changes are reported as mean ± 44 
standard deviation of the absolute scores within each group.  EAMT-SC: electrically-assisted 45 
movement therapy before standard care; SC- EAMT: standard care before electrically-assisted 46 
movement therapy. T1* group mean and standard deviation  was calculated by including T1* 47 
evaluations instead of T1 evaluations for the two patients who took a longer washout period. 48 
 49 
  50 
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Supplementary material 51 
Supplementary Figure 1 – Change in primary outcome metric including the follow-up 52 
assessment. 53 
54 
Absolute change in FMA-UE at all evaluations, displayed by group. Therapy was only provided 55 
between T0 and T1 and between T1 and T2. T1 was collected of the beginning of the washout 56 
week between the two therapies. T1* group average was calculated by including T1* evaluations 57 
instead of T1 evaluations for the two patients who took a longer washout period.  58 
 59 
  60 
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Supplementary Figure 2 – Single-patient primary outcome data. 61 
  62 
9 
 
A) Graphical representation of the change of FMA-UE scores for each patient. Each trajectory 63 
represents the evolution of FMA-UE score of a patient.  B) Individual FMA-UE scores at T0, T1, 64 
T2, and T3 evaluations. Patients 4 and 9 took a longer washout time than the others, and were 65 
screened at T1* before starting the second therapy. Relative improvements for those two patients 66 
were calculated as T1-T0 and T2-T1*. Patient 7 dropped out after receiving SC for medical 67 
reasons unrelated to this study. We also report the change of FMA-UE score after both therapies 68 
with respect to baseline (i.e. T2-T0) and the overall change 18 weeks after therapy start with 69 
respect to baseline (i.e. T3-T0).  70 
 71 
 72 
 73 
  74 
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Supplementary Table 1 – Single-patient demographics and lesions characteristics. 75 
 76 
TSE: time since event. TACI: total anterior circulation infarct. PACI: partial anterior circulation 77 
infarct. Lesion side referred to R: right hemisphere, and L: left hemisphere. All patients 78 
presented an ischemic lesion. Lesion volumes and lesion locations were assessed by means of 79 
magnetic resonance imaging performed before trial start, except for the marked cases where data 80 
were †: images were retrieved from former MRI scan and ‡: images were retrieved from former 81 
CT scan.  82 
